Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: Side effect of the prednisone or better control of disease activity?

Arthritis Care and Research

Volumn 65, Issue 1, 2013, Pages 88-93

  Jurgens, Maud S ^a   Jacobs, Johannes W G ^a   Geenen, Rinie ^a   Bossema, Ercolie R ^a   Bakker, Marije F ^a   Bijlsma, Johannes W J ^a   Van Albada Kuipers, Iet A ^b   Ehrlich, Johan C ^c   Lafeber, Floris P J G ^a   Welsing, Paco M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c TERGOOI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; PREDNISONE;

ADULT; ARTICLE; BODY MASS; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; REMISSION; RHEUMATOID ARTHRITIS; WEIGHT GAIN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PREDNISONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84871812783     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21797     Document Type: Article

References (18)

1. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
2. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD,. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 450-62.
3. Gremese E, Ferraccioli G,. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582-9.
4. Kitas GD, Erb N,. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 607-13.
5. Wolfe F, Freundlich B, Straus WL,. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.
6. Erhardt CC, Mumford PA, Venables PJ, Maini RN,. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13.
7. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2009; 69: 325-31.
8. Walsmith J, Roubenoff R,. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 89-99.
9. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62: 3173-82.
10. Brown RA, Spina D, Butt S, Summers GD,. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol 2012; 31: 455-61.
11. Rajbhandary R, Khezri A, Panush RS,. Rheumatoid cachexia: what is it and why is it important? J Rheumatol 2011; 38: 406-8.
12. Kirwan JR, Bijlsma JW, Boers M, Shea BJ,. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1: CD006356.
13. Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW,. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6: 693-702.
14. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al, for the Utrecht Rheumatoid Arthritis Cohort Study Group. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156: 329-39.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
16. Munro R, Capell H,. Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 1997; 56: 326-9.
17. Stahn C, Buttgereit F,. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
18. Stahn C, Lowenberg M, Hommes DW, Buttgereit F,. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.